A New Chapter in Reihaneh Pharmaceutical: Honoring the Past, Ushering in the Future

Barekat Health & Pharmaceutical Group – In a ceremony marked by both reverence and renewal, the formal farewell of Mr. Arash Siavoshi Nejad and the introduction of Dr. Mansour Nekouei-Nia as the new CEO of Reihaneh Pharmaceutical Company was held in the presence of senior executives from the Barakat Health and Pharmaceutical Group, alongside managing directors from affiliated subsidiaries.

During the event, heartfelt appreciation was extended to Mr. Siavoshi Nejad for his tireless dedication and the remarkable milestones achieved under his leadership. His tenure was lauded for significant advancements in production processes, enhanced operational efficiency, and the consolidation of Reihaneh’s standing in the national pharmaceutical market. His unwavering commitment to strategic improvement and professional excellence was consistently evident throughout his directorship.

In line with these reflections, Mr. Ali Mortazavi highlighted the pivotal and strategic role of Reihaneh Pharmaceutical within the broader manufacturing portfolio of the Barekat Group. He underscored the imperative for innovation, diversification of the product pipeline, and a forward-looking emphasis on export markets. Expressing optimism, he noted that the appointment of a new CEO heralds the beginning of a transformative era of expansion and innovation for the company.

Dr. Hassan Jalili, emphasized the critical importance of a science-driven, technologically progressive, and reform-oriented approach in the new phase of leadership. He reaffirmed that the Barakat Health and Pharmaceutical Group remains resolute in advancing its subsidiaries through the leadership of capable and visionary executives.

The ceremony concluded with the official appointment of Dr. Mansour Nekouei-Nia as the new Chief Executive Officer of Reihaneh Pharmaceutical Company. This leadership transition marks a turning point—an inflection moment symbolizing the commencement of a new era characterized by growth, innovation, and an elevated contribution to the advancement of Iran’s pharmaceutical sector.